Zacks.com on MSN2d
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
FiercePharma2d
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
MedPage Today3d
Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?
(JAMA Network Open) A phase III trial of the antibody-drug conjugate patritumab deruxtecan in non-small cell lung cancer met the primary endpoint of progression-free survival, although two deaths not ...
Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise
MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Daiichi Sankyo and MSD’s ADC improves progression-free survival in NSCLC trial
In the trial, most interstitial lung disease events were observed to be low grade, with two grade 5 ILD events being reported ...
The Pharma Letter4d
Patritumab deruxtecan closer to market
The HERTHENA-Lung02 Phase III trial of patritumab deruxtecan in advanced EGFR-mutated NSCLC patients who received prior EGFR ...
pharmaphorum4d
After FDA no, MSD/Daiichi post new data with lung cancer ADC
The result is a welcome endorsement of patritumab derxutecan's potential after the HER3-directed antibody-drug conjugate (ADC ...
precisionmedicineonline5d
Merck, Daiichi Sankyo to Discuss Antibody-Drug Conjugate Data in EFGR-Mutated NSCLC With Regulators
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
BioSpace5d
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...
Daiichi Sankyo, Merck's Patritumab Deruxtecan Meets Primary Goal In HERTHENA-Lung02 Phase 3 Study
Merck & Co Inc. (MRK) on Tuesday said HERTHENA-Lung02 phase 3 study evaluating Daiichi Sankyo and Merck's patritumab deruxtecan in ...
FierceBiotech5d
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...